Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies / Paul E. Keck en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Título : Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies Tipo de documento: texto impreso Autores: Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 27-35 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134 [artículo] Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies [texto impreso] / Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor . - 2023 . - pp. 27-35. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134

---

1 (1 - 1 / 1)